The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Carcinomas of unknown primary treated with molecularly guided therapies and immune checkpoint inhibitors: A subset from the I-PREDICT N-of-1 Precision Oncology study.
 
Eric Roth
No Relationships to Disclose
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix; XZOM
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Daiichi Sankyo; Datar Genomics; Iylon; Jackson Laboratory for Genomic Medicine; Lanauria Therapeutics; Nova; Precirix; Recordati; Roche; Ryght AI
Speakers' Bureau - AstraZeneca; AstraZeneca; CureMatch; OneCell; Recordati; Tempus
Research Funding - Biological Dynamics (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Guardant Health (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); NCI (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Sysmex (Inst)
Travel, Accommodations, Expenses - NCI SWOG; TargetCancer Foundation
Other Relationship - See Comments
 
Daisuke Nishizaki
No Relationships to Disclose
 
Yuji Uehara
Honoraria - Chugai Pharma
 
Hirotaka Miyashita
No Relationships to Disclose
 
Ryosuke Okamura
No Relationships to Disclose
 
Michael Hahn
Employment - Illumina (I)
Stock and Other Ownership Interests - Illumina (I)
 
Mina Nikanjam
No Relationships to Disclose
 
Paul Fanta
No Relationships to Disclose
 
David Piccioni
Consulting or Advisory Role - GlaxoSmithKline; Novartis
 
Hitendra Patel
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Rigel (Inst)
 
Ramez Eskander
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; BioNTech SE; Daiichi Sankyo/Lilly; Eisai; Gilead Sciences; GlaxoSmithKline; Immunogen; Merck; Myriad Genetics; Pfizer; PMV Pharma; Regeneron; Seagen
Research Funding - Acrivon Therapeutics (Inst); AstraZeneca (Inst); Corcept Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nivectis (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Eisai; Merck
Other Relationship - GOG Foundation
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Precede Bio; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Jeffrey Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Tango Therapeutics
Research Funding - Foundation Medicine
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
Scott Lippman
Stock and Other Ownership Interests - Acurion; Biological Dynamics; Sympto Health
Consulting or Advisory Role - Biological Dynamics; io9, LLC; Sympto Health
Patents, Royalties, Other Intellectual Property - Mission: Co-founder of a company (io9) and co-developer of IP related to genomic predictive biomarkers and novel therapeutics that will power precision immunotherapy, particularly in the clinical use of immune checkpoint inhibitors.; PCT/U.S. Provisional Application Serial No. 63/483,237 on February 3, 2023 SD2022-273-2; 009062-8474.US01] 009062-8474.WO00 Title: ARTIFICIAL INTELLIGENCE ARCHITECTURE FOR PREDICTING CANCER BIOMARKERS (Inst); PCT/US2022/015363 on February 4, 2022 (International Application) Title: METHODS AND BIOMARKERS IN CANCER Legal Name of Inventors: Scott M. Lippman (Inst); U.S. Provisional Application Serial No. 63/412,835 on October 3, 2022 PATENT UCSD-DFCI Ref. No. SD2023-089 Title: GENETICALLY-DEFINED IMMUNE-CHECKPOINT INHIBITOR RESISTANCE IN AGGRESSIVE PRECURSORS OF HPV— HEAD AND NECK SQUAMOUS CANCER Legal name of inv (Inst)
 
Jason Sicklick
Stock and Other Ownership Interests - CureMatch; Oncureon, Inc.; Personalis
Consulting or Advisory Role - BlossomHill; CureMatch; Deciphera; GlaxoSmithKline; Kura Oncology; Kureha; SpringWorks Therapeutics
Speakers' Bureau - Deciphera; SpringWorks Therapeutics
Patents, Royalties, Other Intellectual Property - Methods for Diagnosing and Treating Drug Resistant Cancers (Inst)
Expert Testimony - Arias Sanguinetti; CUTT, KENDELL & OLSON
Travel, Accommodations, Expenses - Deciphera
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex